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Abstract
Background: The EQ-5D is a generic questionnaire which generates a health profile as well as index scores for health-
related quality of life that may be used in cost-utility analysis.
Aims of the study: To examine validity and responsiveness of the EQ-5D in patients with anxiety disorders.
Methods: 389 patients with anxiety disorders completed the EQ-5D at baseline and 6-month follow-up. Subjective 
measures of quality of life (WHOQOL-BREF) and psychopathology (BAI, BDI-II, BSQ, ACQ, MI) were used for comparison. 
Validity was analyzed by assessing associations between EQ-5D scores and related other scores. Responsiveness was 
analyzed by calculating effect sizes of differences in scores between baseline and follow-up for 3 groups indicating 
more, constant or less anxiety. Meaningful difference scores for shifting to less or more anxiety were derived by means 
of regression analysis.
Results: 88.4% of respondents reported problems in at least one of the EQ-5D dimension at baseline; the mean EQ VAS 
score was 63.8. The EQ-5D dimension most consistently associated with the measures used for comparison was 
'anxiety/depression'. EQ VAS and EQ-5D index scores were highly correlated (|r|>0.5) with scores of the WHOQOL-BREF 
dimensions 'physical', 'mental' and 'overall' as well as BAI and BDI-II. The EQ-5D index tended to be the most responsive 
score. Standardized meaningful difference scores were not significantly different between EQ VAS, EQ-5D index and 
measures used for comparison.
Conclusions: The EQ-5D seems to be reasonably valid and moderately responsive in patients with anxiety disorders. 
The EQ-5D index may be suitable for calculating QALYs in economic evaluation of health care interventions for patients 
with anxiety disorders.
Trial registration: Current Controlled Trials ISRCTN15716049
Background
The EQ-5D is a short generic patient-rated questionnaire 
for subjectively describing and valuing health-related 
quality of life (HRQOL); it is often used as an outcome 
measure in both clinical and health care services research 
(see complete list of references provided by the EuroQol 
Group [1]). The EQ-5D provides a descriptive profile of 
HRQOL as well as a subjective overall rating of the 
patient's own health state on the day of administration by 
means of a visual analogue scale (EQ VAS) [2,3]. Further-
more, according to a particular set of preference values 
derived from surveys of the general population, an index 
score (EQ-5D index) is assigned to all possible descriptive 
profiles of the EQ-5D. The EQ-5D index reflects the pref-
erences of the community for EQ-5D health states. Pref-
erence-based scores are often used for calculating 
quality-adjusted life years (QALYs) in economic evalua-
tion (cost-utility analysis) of health care [4,5]. According 
to a recent review, the EQ-5D is the most frequently used 
instrument to calculate QALYs [6].
Since decisions about the suitability of the EQ-5D in eco-
nomic evaluation need to be based on a clear conceptual 
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framework, the validity of the EQ-5D has been demon-
strated for various diseases as well as the general popula-
tion (see EuroQol Group's complete list of references). 
Although QALYs have been recommended as a measure 
of health effects in patient with anxiety disorders [7], and 
some evaluations of care for this patient group have 
already used the EQ-5D [8,9], little is known about the 
psychometric properties of the EQ-5D in patients with 
anxiety disorders: Supina et al. showed that the EQ-5D 
may be useful in distinguishing subjects with anxiety 
from mentally healthy subjects [10]. In a sample of 
patients with mood and/or anxiety disorders Lamers et 
al. found the EQ-5D index to capture improvements 
based on quartiles of the patient-rated Symptom Check 
List 90R (SCL-90R) [11]. Whynes et al. showed that the 
EQ-5D was responsive to differing degrees of anxiety 
identified by the Hospital Anxiety and Depression Scale's 
anxiety sub-scale in a sample of women with lowgrade 
cytological abnormalities detected at routine screening 
for cervical cancer [12].
The purpose of our study was to analyze the EQ-5D's psy-
chometric properties in patients with anxiety disorders in 
more detail. More precisely, we analyzed its construct 
validity (Does the EQ-5D adequately measure the under-
lying construct?) as well as its responsiveness (Is the EQ-
5D able to detect health state changes over time?).
Methods
Subjects and study design
Our study used a patient sample which was enrolled in a 
cluster randomised controlled trial (CRCT; trial registra-
tion: Current Controlled Trials ISRCTN15716049). For 
this trial, 8472 consecutive patients under treatment were 
screened for anxiety disorders with the German version 
of the Patient Health Questionnaire (PHQ-D) [13] at 54 
practices of general practitioners (GPs) in the city area of 
Leipzig, Germany, from August to November 2005. 7.4% 
of the patients (n = 629) screened positive for panic disor-
der (F41.0), panic disorder with agoraphobia (F40.01), 
generalized anxiety disorder (F41.1) or unspecified anxi-
ety disorder (F41.9) according to ICD-10 criteria [14]. 
Finally, 46 GPs participated in the CRCT, and 389 posi-
tively screened patients agreed to participate in the base-
line assessment (t0) conducted from January to March 
2006. Of the participating patients, 218 (56.0%) suffered 
from panic disorder, 114 (29.3%) from generalized anxi-
ety disorder and 57 (14.7%) from unspecified anxiety dis-
order. After stratification of GP practices (clusters) by the 
number of patients, the clusters were randomly allocated 
to a control group (CG: 23 GP practices, n = 188 patients) 
and an intervention group (IG: 23 GP practices, n = 201 
patients). GPs in the intervention group received training 
on diagnosis and treatment of anxiety disorders com-
bined with a consultation offer during 6 months. After 6 
months (t1), patients were re-assessed using the same set 
of measures described below. Drop-out rates were rela-
tively low, resulting in 335 participating patients at t1 
(CG: n = 163, IG: n = 172). Design and results of the 
CRCT have been reported in detail elsewhere [15]. As the 
intervention was not effective, with no differences 
between IG and CG in any outcome measure assessed, 
patients of the IG and CG were pooled for the analyses 
presented here. Socio-demographic characteristics of the 
sample at t0 are outlined in Table S1, Additional file 1.
The research protocol of the study was reviewed and 
approved by the Committee of Research Ethics at the 
Medical Faculty of the University of Leipzig.
Measures
Besides the EQ-5D, all patients were assessed by a set of 
patient-rated questionnaires including the World Health 
Organization Quality of Life-Bref questionnaire (WHO-
QOL-BREF), the Beck Depression Inventory (BDI-II) as 
well as anxiety-specific measures of psychopathology 
(Beck Anxiety Inventory (BAI), Body Sensation Ques-
tionnaire (BSQ), Agoraphobic Cognitions Questionnaire 
(ACQ), and Mobility Inventory (MI)).
EQ-5D
The EQ-5D questionnaire comprises five questions 
(items) relating to current problems in the dimensions 
'mobility', 'self-care', 'usual activities', 'pain/discomfort', 
and 'anxiety/depres-sion' [2,3,16]. Responses in each 
dimension are divided into three ordinal levels coded (1) 
no problems, (2) moderate problems, (3) extreme prob-
lems. This part, called the EQ-5D descriptive system, 
provides a five-dimensional description of health status 
which can be defined by a five-digit number. For example, 
the state '11122' indicates no problems in mobility, self-
care, and usual activities, but moderate pain/discomfort 
and moderate anxiety/depression. Theoretically, 35 = 243 
different health states can be defined. The EQ-5D 
descriptive system is followed by the EQ VAS, which is 
similar to a thermometer, ranging from 0 (worst imagin-
able health state) to 100 (best imaginable health state). 
The EQ VAS records the respondent's subjective overall 
rating of his/her own health state on the day of adminis-
tration (EQ VAS score).
EQ-5D index
The EQ-5D index represents societal preference values 
for the full set of 243 EQ-5D health states with the state 
'11111' (perfect health) and 'death' a priori (i.e. by defini-
tion) being assigned values of 1 and 0, respectively. The 
EQ-5D index scores used in the present study were 
obtained from a random sample of the British general 
population (n = 2997), where the Time Trade-Off (TTO) 
method was used to derive preference values for given 
EQ-5D health states [17]. The British EQ-5D index has 
been used in numerous international studies, including König et al. Health and Quality of Life Outcomes 2010, 8:47
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the field of mental health [18]. Accordingly, to each 
patient's health status on the descriptive system of the 
EQ-5D, an index score was assigned, ranging from 1.0 for 
the EQ-5D health state 11111 to -0.59 for the worst possi-
ble health state (33333) [17].
WHOQOL-BREF
The WHOQOL-BREF is a generic questionnaire for sub-
jectively measuring quality of life in the previous two 
weeks [19]. It is an abbreviated version of the WHOQOL-
100 questionnaire which assesses a person's perception of 
their life situation in the context of their culture and value 
system and consists of 26 items, each rated on a 5-point 
Likert scale. Unlike other instruments, the WHOQOL-
BREF takes a broader concept of quality of life, which is 
not restricted to health-related aspects. Since numerous 
international centers participated in the development of 
the WHOQOL it is a culturally independent instrument. 
From the 26 items, scores for four domains can be 
derived, namely 'physical health' (7 items), 'mental health' 
(6 items), 'social relationships' (3 items) and 'environ-
ment' (8 items). In addition, the WHOQOL-BREF pro-
vides a score for overall quality of life, based on two items. 
All scores range from 1 (worst) to 100 (best). Domain and 
overall scores were calculated according to the scoring 
algorithms provided by the manual of the German ver-
sion of the WHOQOL-BREF. The psychometric proper-
ties of the WHOQOL-BREF are considered good with an 
internal consistency (Cronbach's α) of the subscales 
between 0.76 and 0.88. The validity has been established 
through a good discriminative ability between healthy 
and ill subjects [20].
BAI
The BAI is a 21-item measure designed to assess the 
severity of self-reported anxiety [21]. Responses on each 
item range from 0 (not at all bothered) to 3 (severely both-
ered). The total score for all 21 items ranges from 0 to 63, 
with higher scores indicating higher levels of anxious-
ness. The BAI has excellent internal consistency (Cron-
bach's α = 0.93) [22] and good test-retest reliability (r = 
0.73 to 0.83) [21,23,24]. Convergent validity in clinical 
samples was r = 0.51 with the Hamilton Anxiety Scale 
[21], r = 0.58 with the State-Trait-Anxiety-Inventory 
(STAI) Trait and r = 0.47 with the STAI State [24]. Its dis-
criminant validity was superior that of the STAI [24]. The 
BAI is one of the most commonly used measures to 
assess the construct of anxiety [25], because it is easy to 
administer, to complete, and to interpret.
BDI-II
The BDI-II is a 21-item self-report depression screening 
measure [26]. The items ask respondents to endorse 
statements characterizing how they have been feeling 
throughout the last week. Here each item is rated on a 
scale ranging from 0 to 3, with a possible range of total 
scores from 0 to 63. Higher scores represent a higher 
intensity level of depression. Scores of 0 to 13 denote 
minimal depression, scores of 14 to 19 denote mild 
depression, scores of 20 to 28 denote moderate depres-
sion, and scores of 29 to 63 denote severe depression.
BSQ
The BSQ is 17-item self-report instrument to evaluate 
fear of the physical sensations generally associated with a 
panic attack [27]. The BSQ has very good internal consis-
tency (Cronbach's α = 0.87) and moderate test-retest reli-
ability (r = 0.67). It showed good construct validity with a 
variety of measures of psychopathology.
ACQ
The ACQ is a 14-item self-report instrument which mea-
sures the frequency of fearful cognitions associated with 
panic attacks and agoraphobia [27]. In a sample of outpa-
tients with agoraphobia, internal consistency measured 
by Cronbach's α was 0.80.
MI
The MI is a 29-item self-report instrument measuring the 
severity of behavioral avoidance [28,29]. Internal consis-
tency measured by Cronbach's α ranged from α = 0.91 to 
0.97, test-retest reliability ranged from r = 0.75 to 0.90, 
and good construct validity has been shown. The MI is 
divided into two subscales, Avoidance Alone (MIA) and 
Avoidance Accompanied (MIB), with good internal con-
sistency for both subscales.
Scores of BSQ, ACQ, MIA and MIB each may range from 
0 (best) to 4 (worst). German versions of these instru-
ments are described in [30].
Psychometric analysis
The EQ-5D is a generic instrument intended to measure 
overall HRQOL in a wide range of populations, including 
patients with anxiety disorders. Yet, the extent to which 
the EQ-5D is successful in measuring HRQOL in patients 
with anxiety disorders has not been examined in depth. 
Therefore the approach taken in this study was to com-
pare the EQ-5D with other measures of psychopathology 
and quality of life. Thereby we assessed aspects of the 
EQ-5D's construct validity and responsiveness.
Construct validity refers to the extent to which the mea-
surement corresponds to theoretical concepts (con-
structs) concerning the phenomenon under study [31]. In 
this study we hypothesized that there was an association 
between the scores of the EQ-5D and of measures of psy-
chopathology and quality of life. While most applied 
measures of psychopathology specifically aim at measur-
ing anxiety, the WHOQOL-BREF aims at measuring 
overall HRQOL similar to the EQ-5D, yet in a more 
detailed manner with the 'mental health' domain score 
being based on six items.
Thus, construct validity of the EQ-5D descriptive system 
was assessed by analysing the association between the 
response level of EQ-5D items and the scores of the other König et al. Health and Quality of Life Outcomes 2010, 8:47
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measures used in the study. Specifically, we hypothesized 
that the association was particularly strong between the 
EQ-5D dimension 'anxiety/depression' and the anxiety-
specific BAI score as well as the mental health domain 
score of the WHOQOL-BREF. Construct validity of the 
EQ VAS and the EQ-5D index was assessed by analysing 
their correlation with the scores of the other measures 
used in the study. Specifically, we hypothesized that EQ 
VAS and EQ-5D index scores were strongly correlated 
with the BAI score and the mental health domain score of 
the WHOQOL-BREF.
Responsiveness was assessed by the criteria of the United 
States Food and Drug Administration (FDA), which 
raised a draft on patient reported outcomes including 
methods to calculate responsiveness and to interpret the 
detected changes as meaningful [32]. The recommended 
best practice in the evaluation of responsiveness is the 
calculation of various distribution-based estimates (i.e. 
effect size, standardized response mean) under several 
anchor-based criteria (i.e. patient or clinician ratings of 
global improvement) [33]: on this note, the anchor-based 
criterion is used as an external indicator to assign 
patients into groups reflecting 'no change' and a '(small) 
positive/negative change' [34,35]. Guidance on interpre-
tation of the magnitude of a distribution-based estimate, 
for example, whether differences in scores are viewed as 
meaningful, is provided [36,37]. Nonetheless, there is no 
gold standard in terms of whether the difference in scores 
is meaningful, but there are some methods which one will 
find very useful in interpretation; for example, one defini-
tion of a meaningful difference is based on the 'minimal 
important difference' (MID) [34,35]. In practice, the MID 
is viewed as the difference in scores between the group 
with 'no change' and the group with 'small positive/nega-
tive change'.
Data analytic procedures
The non-parametric Spearman rank correlation coeffi-
cient (rs) was used for analysing correlations, since the 
EQ VAS score and the EQ-5D index were not normally 
distributed. Correlation was considered large for |rs|≥0.5, 
moderate for 0.3≤|rs|<0.5, and small for 0.1≤|rs|<0.3 [36]. 
Responsiveness was compared by paired t-test statistics, 
effect sizes (ES) and standardized response mean (SRM). 
The method to calculate ES was: ES = M1-M0/SDbaseline; 
where M0 is the mean score of the baseline assessment, 
M1 the mean score of the follow-up assessment, and 
SDbaseline the standard deviation of the baseline assess-
ment. The method to calculate SRM was: SRM = M1-M0/
SDM1-M0; where the numerator remains the same as for 
calculating ES, but the denominator represents the SD of 
the difference in scores. We considered an absolute mag-
nitude of difference scores expressed by ES and SRM 
<|0.20| as trivial, from ≥|0.20| to <|0.50| as small, from 
≥|0.50| to <|0.80| as medium, and ≥|0.80| as large based 
on Cohen's interpretation guidelines [36]. Meaningful 
differences in health status were estimated as follows [32]: 
Patients whose psychopathology on the BAI increased by 
more than 0.5 SD of the BAI baseline score from t0 to t1 
were categorized into a group labelled 'more anxiety' (n = 
43). Patients whose BAI score decreased by more than 0.5 
SD were categorized into a group labelled 'less anxiety' (n 
= 83). All other patients were categorized as 'no shift in 
anxiety' (n = 124). Categorizing of patients was per-
formed independently of any intervention. Five linear 
regression models with the difference scores of EQ VAS, 
EQ-5D index, WHOQOL-BREF domain score 'mental 
health', BSQ and ACQ used as dependent variables were 
estimated. Each dependent variable was regressed on 
dummy variables for 'more anxiety', 'less anxiety' as well 
as respondents' age, the BDI-II score and the score of the 
respective measure at baseline. The absolute values of 
coefficients of the dummy variables were tested for signif-
icant differences within each regression model. For better 
comparison between the models, difference scores and 
baseline scores were standardized to SD = 1 and mean = 
0. Cross-model hypotheses were tested using seemingly 
unrelated estimation (SUEST) [38]. Statistical signifi-
cance of raised R2 due to incorporation of the anchor was 
tested using LR-tests with hierarchical nested regression 
models. For statistical testing, the level of significance 
was set at α = 0.05. Calculations were performed using 
the software package STATA [39].
Results
EQ-5D scores
Problems in at least one of the EQ-5D dimension were 
reported by 88.4% of the respondents at baseline. Most 
frequent were problems in the dimension 'anxiety/
depression' (77.4%), followed by 'pain/discomfort' 
(71.5%), 'usual activities' (40.8%), 'mobility' (23.0%) and 
'self-care' (3.9%). In all dimensions problems were 
reported more frequently than in a German general pop-
ulation sample [40] (Figure 1).
The most frequently reported EQ-5D health state was the 
one with moderate problems in the two dimensions 
"pain/discomfort" and "anxiety/depression" (11122), 
which was indicated by 21.2% of all respondents (Table 
S2, Additional file 2). The four EQ-5D health states 
reported most frequently covered 59.4% of all respon-
dents.
The mean (median) was 63.8 (70) for the EQ VAS score 
and 0.66 (0.73) for the EQ-5D index (Table S3, Additional 
file 3). The proportion of respondents with the best possi-
ble score was 1.0% for the EQ VAS and 11.6% for the EQ-
5D.König et al. Health and Quality of Life Outcomes 2010, 8:47
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Score of measures used for comparison
Table S4, Additional file 4 presents the scores of the mea-
sures used for comparison with the EQ-5D at baseline. 
The mean scores of WHOQOL-BREF domains 'physical 
health', 'social relationships' and 'environment' were 
around 60 and those of 'mental health' and the 'overall' 
score were around 50. The mean BAI score was 20.4: the 
mean BDI-II score (16.4) indicated mild depression on 
average.
Construct validity
Table S5, Additional file 5 shows the mean scores of the 
measures used for comparison categorized by the 
patients' level of response to EQ-5D items at baseline. 
Since for all EQ-5D items the number of observations in 
the category 'extreme problems' was small, the categories 
'moderate problems' and 'extreme problems' were col-
lapsed into one category.
For almost all EQ-5D dimensions, different response lev-
els were associated with significantly different scores of 
the WHOQOL-BREF domains and measures of psycho-
pathology. As hypothesized, the strongest association was 
found between the EQ-5D dimension 'anxiety/depres-
sion' and the BAI score: For respondents reporting mod-
erate or extreme problems in the EQ-5D dimension 
'anxiety/depression', the mean BAI score was 23.7, 
whereas for those reporting no problems in this dimen-
sion it was 9.2. This difference was highly significant and 
corresponds to an ES of d = 1.53. Also, as hypothesized, a 
very strong association of the EQ-5D dimension 'anxiety/
depression' with the 'mental health' domain score of the 
WHOQOL-BREF (d = 1.44) was found, but also with the 
BDI-II (d = 1.52). ES of all other measures were smaller, 
yet still large (|d|>0.8), except for the WHOQOL-BREF 
domain score 'environment' and the MI scores. For differ-
ent levels of all other EQ-5D dimensions, ES of the 
WHOQOL-BREF domain score 'physical health' were 
largest (always |d|>0.8).
The WHOQOL-BREF domain score 'physical health' and 
the 'overall' score showed large ES for different levels of 
all EQ-5D dimensions, whereas the ES of the WHOQOL-
BREF domain score 'mental health' was only large for dif-
ferent levels of the EQ-5D dimensions 'self-care' and 'anx-
iety/depression'. The scores of BAI and BDI-II showed 
large ES for different levels of the EQ-5D dimensions 
'anxiety/depression', 'usual activities' and 'self-care'. The 
scores of BSQ and ACQ showed large ES only for differ-
ent levels of the EQ-5D dimension 'anxiety/depression', 
Figure 1 Distribution of responses to items of EQ-5D descriptive system in patient sample (n = 389) and general population (n = 3552) [40]. 
In the patient sample there were 7 missing values for the EQ-5D items 'mobility', 'self-care', 'usual activities', 10 missing values for the item 'pain/dis-
comfort' and 8 missing values for the item 'anxiety/depression'.
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whereas the scores MIA and MIB did not show any large 
ES.
Regarding the construct validity of the EQ VAS score and 
EQ-5D index, Table S6, Additional file 6 shows large cor-
relations with the BAI and the WHOQOL-BREF domain 
'mental health', as hypothesized. Yet, correlation was 
strongest with the WHOQOL-BREF domain 'physical 
health', and also large with the BDI-II and the WHO-
QOL-BREF 'overall' score. All correlations of the EQ VAS 
score and the EQ-5D index with scores of BSQ, ACQ, 
MIA and MIB were weaker and only moderate.
Responsiveness of the EQ VAS and the EQ-5D indices 
compared with other measures
Table S7, Additional file 7 shows the responsiveness sta-
tistics (t-statistics, ES and SRM) for all outcome mea-
sures, split by the anchor of change defined by the BAI 
score. While the t-statistics indicated significant differ-
ences in scores of all outcome measures for patients who 
shifted to 'more anxiety' or 'less anxiety', large ES were 
only observed for the EQ-5D index in the category "more 
anxiety". For all other measures, ES were mostly trivial to 
medium in the categories "more anxiety" and "less anxi-
ety". SRM were never larger, but some were medium, 
especially in the category 'more anxiety'. In the category 
'constant anxiety', ES and SRM were negligible for all out-
come measures, and t-statistics indicated no significant 
differences.
Meaningful differences of the EQ VAS and the EQ-5D index 
compared with other measures
Table S8, Additional file 8 presents the results of the five 
regression models. Regression coefficients of the dummy 
variables representing a shift to 'more anxiety' were all 
significant and tended to have larger absolute values than 
those representing a shift to 'less anxiety', which were not 
significant for the WHOQOL-BREF-mental domain 
score. The EQ-5D index indicated a significant gain of 
0.07 score points (standardized: 0.29) as a meaningful dif-
ference associated with a shift to 'less anxiety' and a sig-
nificant reduction of -0.15 (standardized: -0.67) as a 
meaningful difference associated with a shift to 'more 
anxiety'. The effects of all measures' baseline scores were 
significant and negative indicating larger differences 
between the two assessments with smaller scores at the 
baseline. Co-morbid depression measured by the BDI-II 
did not affect meaningful difference scores of any of the 
measures except for a small effect on the BSQ meaningful 
difference score.
When testing intra-model hypotheses, the difference 
scores in the categories 'less anxiety' and 'more anxiety' 
were significantly different for all outcome measures, 
whereas the absolute values of difference scores in both 
categories were not significantly different. The inclusion 
of the dummy variables for 'more anxiety' and 'less anxi-
ety' resulted in a significant increase of the R2 in all six 
models. When testing cross-model hypotheses with 
SUEST, the effects (coefficient values) of 'more anxiety' (P 
= 0.30), 'less anxiety' (P = 0.42) and 'constant anxiety' (P = 
0.30) on standardized outcome measures were not signif-
icantly different in the five regression models. Effects of 
standardized baseline scores differed significantly across 
the six outcome measure (P = 0.03).
Discussion
Although the EQ-5D has been used in patients with anxi-
ety disorders before [8,9], little data on its psychometric 
properties in this patient group have been published [10-
12].
Patients with anxiety disorders were mostly burdened in 
the EQ-5D dimensions 'anxiety/depression', 'pain/dis-
comfort', and 'usual activities'. Only 11.4% of respondents 
reported no problems in any of the EQ-5D dimensions, 
and only 1.0% rated their health states with the best pos-
sible score (100) on the EQ VAS. Thus, the ceiling effect 
of the EQ-5D which has been described repeatedly in 
other patient groups [41] as well as in samples of the gen-
eral population [42] seems to be less pronounced in this 
patient group. The EQ-5D discriminated well between 
patients with anxiety disorders and the general popula-
tion as anxiety patients reported problems in all dimen-
sions more frequently. This goes in line with findings of 
Supina et al. who showed increased odds of anxiety 
patients for reporting problems in all EQ-5D dimensions 
compared to mentally healthy subjects [10].
The EQ-5D dimension most consistently associated with 
the subjective measures of psychopathology and quality 
of life was 'anxiety/depression' followed by the dimen-
sions 'self-care' and 'usual activities'. As hypothesized, the 
strongest association was found between the EQ-5D 
dimension 'anxiety/depression' and the BAI score. This is 
indicative of an adequate construct validity of the EQ-5D. 
This is also emphasized by the strong correlation of EQ 
VAS and EQ-5D index scores with the BAI score and the 
'mental health' domain score of the WHOQOL-BREF. 
Not surprisingly, association with the BDI-II was also 
strong, as the EQ-5D does not differentiate between anx-
iety and depression. Nevertheless, we would have 
expected to find larger ES and stronger correlations with 
the BSQ and ACQ since these measures are considered to 
be more sensitive than the BAI. Yet being a generic 
HRQOL instrument designed to measure problems in all 
major dimensions of well-being, the EQ-5D inevitably 
has only limited content validity for specific diseases. 
Only one out of five questions of the EQ-5D specifically 
refers to anxiety or mental health.
The EQ-5D index tended to be more responsive than the 
EQ VAS score, showing larger ES and SRM and signifi-König et al. Health and Quality of Life Outcomes 2010, 8:47
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cant coefficients associated with both, shifts to more and 
less anxiety in the regression model analyzing meaningful 
differences. However, when comparing regression coeffi-
cients across the five models using SUEST, no significant 
differences in meaningful differences between the various 
measures were found, pointing at similar responsiveness 
of the EQ-5D and the measures used for comparison.
Although the EQ-5D index seemed more responsive to 
the shift to more anxiety than to the shift to less anxiety 
statistical testing indicated that, while significantly differ-
ent, both response levels did not differ significantly in 
their absolute values. Therefore, greater responsiveness 
of EQ-5D scores for a shift to 'worse health status' than 
for a shift to 'better health status' as reported in a study by 
Günther et al. [43] in patients with depression could not 
be confirmed. One possible explanation might be the less 
pronounced ceiling effect of the EQ-5D in anxiety 
patients. It was argued by Günther [43] that, as a conse-
quence of a ceiling effect, the larger range at the bottom 
of the EQ-5D indices could provide a potential for the 
assessment of larger changes in health state than at the 
compressed top of the scale. An alternative explanation 
might be that our finding is the result of adequate testing.
The 'physical health' domain score of the WHOQOL-
BREF showed strong association with all EQ-5D dimen-
sions as well as strong correlation with EQ VAS and EQ-
5D index scores. Changes in anxiety defined the BAI 
score were often associated with changes in problem lev-
els of EQ-5D dimensions other than 'anxiety/depression'. 
This indicates the important role of psychosomatic 
aspects and somatic comorbidity in patients with anxiety 
disorders. Unfortunately, we did not specifically assess 
co-morbid somatic conditions in our study. Therefore 
responsiveness statistics and estimates for meaningful 
difference scores might be confounded by somatic co-
morbidity which is a limitation of our study. However, 
controlling for mental co-morbidity measured by the 
BDI-II hardly affected meaningful difference scores. Yet, 
somatic co-morbidity may explain the conspicuously 
large ES of the EQ-5D index in the group with more anxi-
ety. In this small group (n = 43), changes in the EQ-5D 
index were largely due changes in the EQ-5D dimension 
'anxiety/depression' and/or 'mobility', the latter possibly 
caused by somatic co-morbidity. However, the fact that 
the corresponding SRM is much smaller (due to a large 
SD of the change score of the EQ-5D) points at the pres-
ence of outliers for which this small patient group is more 
sensitive than the larger groups with constant or more 
anxiety.
A limitation of this study results from including patients 
based on the results of a screening instrument (PHQ-D) 
and not on formal diagnosis of an anxiety disorder. As the 
PHQ has a high specificity (97%) [44], probably most of 
the study participants met formal criteria for anxiety dis-
orders. The mean score of the BAI at baseline was similar 
to mean BAI scores found in other samples of outpatients 
with anxiety disorders [21,24]. On the other hand, the 
comparatively low sensitivity of the PHQ (67%) [44] 
resulted in approximately one third of patients with anxi-
ety disorders being missed, which corresponds to the 
prevalence of 7.6% found in our primary care sample as 
opposed to higher prevalence rates of anxiety found in 
other primary care samples [45].
Although the use of country-specific EQ-5D index scores 
have been recommended, we used the British EQ-5D 
index [17] instead of the German index reported by 
Greiner et al. [46]. The German EQ-5D index was esti-
mated based on a rather small population sample (N = 
334) and must therefore be considered less precise: Ger-
man index scores for all 243 EQ-5D health states were 
estimated from a sample of 36 states using a regression 
model. In particular, scores predicted by the model for 
EQ-5D health states which are frequent in patients with 
anxiety disorders such as 11112 (German EQ-5D index = 
1.0) were much higher than those measured in the gen-
eral population sample due to omitted regression coeffi-
cients. Thus, German EQ-5D index scores must be 
considered preliminary. A further limitation results from 
collapsing the levels "extreme problems" and "moderate 
problems" into one category. As mentioned earlier, the 
combining of levels was done for statistical reasons and 
resulted from the extremely low number of responses but 
might have limited the discriminative ability of the EQ-
5D.
Analyzing the validity of the EQ-5D by determining its 
relationship with the measures used for comparison 
might be problematic, since these measures might lack 
validity for themselves. Yet, psychometric properties 
reported in the literature of BAI, BSQ, ACQ and MI for 
patients with anxiety disorders appear to be good. How-
ever, we used only patient-rated but no clinician-rated 
measures for comparison, which also limits the analysis 
of validity.
Moreover, the responsiveness analysis might have suf-
fered from the absence of a practical clinical criterion. For 
defining the anchors we used the BAI score which, 
because of its excellent psychometric properties, good 
convergent validity and better discriminant validity than 
other measures of anxiety, is the most commonly mea-
sure to assess the construct of anxiety. However, the 
anchors were built by a rather statistical approach which 
does not necessarily imply "meaningfulness". Yet, the sta-
tistical significance of the EQ-5D's responsiveness is 
clearly indicated by significant increase of R2 when the 
BAI-anchor was included in the regression analysis.
Due to differences in the applied measures for compari-
son and in statistical methods, our results are difficult to 
compare with other studies which have analyzed the psy-König et al. Health and Quality of Life Outcomes 2010, 8:47
http://www.hqlo.com/content/8/1/47
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chometric properties of the EQ-5D in patients with psy-
chiatric disorders. Yet, other studies reported slightly 
larger correlations of EQ VAS and EQ-5D index scores 
with the score of the WHOQOL-BREF-mental domain in 
alcohol dependent patients (EQ VAS: r = 0.55; EQ-5D 
index: r = 0.60) [47] and in patients with schizophrenia 
(0.62; 0.58) [48] than our study (0.51; 0.50). Change scores 
of EQ VAS and EQ-5D index associated with changed 
likelihood of HADS-defined anxiety reported by Whynes 
et al. [12] are similar in magnitude to meaningful differ-
ence scores found in our study. However, meaningful dif-
ference scores of the EQ VAS and the EQ-5D index 
estimated in a sample of patients with depression tended 
to be larger, yet based on different anchors [43]. Thus, 
construct validity and responsiveness of the EQ-5D in 
patients with anxiety disorders might be somewhat worse 
than in other psychiatric patients.
Conclusions
The EQ-5D appears to be a reasonably valid instrument 
with moderate responsiveness in patients with anxiety 
disorders. Being a short and easy to administer question-
naire, the EQ-5D may easily be added to disorder-specific 
measures, when overall HRQOL and its valuation are 
considered important outcomes. The EQ-5D index may 
be suitable for calculating QALYs in economic evaluation 
of health care interventions for patients with anxiety dis-
orders. Future studies should also use clinician-rated 
measures for analyzing validity and responsiveness.
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